NCT03497923View on ClinicalTrials.gov

Interaction Between Magnesium and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

April 12, 2023

Study Completion Date

April 13, 2023

Conditions
Neuromuscular Blockade
Interventions
DRUG

Magnesium Sulfate

After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.

Trial Locations (2)

1211

University Hospital of Geneva, Anesthesia Department, Geneva

1951

Hôpital du Valais, Sion

All Listed Sponsors
collaborator

Hôpital du Valais

OTHER

lead

Christoph Czarnetzki

OTHER

NCT03497923 - Interaction Between Magnesium and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block | Biotech Hunter | Biotech Hunter